• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Mardepodect Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755358

Mardepodect is an effective and selective PDE10A inhibitor (IC50: 0.37nM). Mardepodect has >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Mardepodect, Inhibitor
Full Product Name
Mardepodect
Product Synonym Names
PF-2545920
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
392.45
Solubility
DMSO: 45mg/mL (114.66mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C25H20N4O
SMILES
CN(N=C1C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C=C1C5=CC=NC=C5
CAS Number
898562-94-2
Target & IC50
Others
In Vitro
Mardepodect is active (ED50: 1mg/kg), in the conditioned avoidance response assay. Administration of Mardepodect to mice induces a dose-dependent increase in striatal cGMP[2].

Product References and Citations for Mardepodect, inhibitor

Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment,of schizophrenia. J Med Chem, 2009, 52(16), 5188-5196.
Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment,of schizophrenia. J Med Chem, 2009, 52(16), 5188-5196.
Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331(2), 574-590.
Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331(2), 574-590.

Other Notes

Small volumes of Mardepodect, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Mardepodect purchase

MBS5755358 is an inhibitor targeting Mardepodect.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000